ArticleJournal of medical biochemistry2025
PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis. Methods: A total of 71 ACS patients were enrolled in this study from April 1, 2022, to June 31, 2022. Patients were randomly assigned to two groups: one group received statin therapy combined with PCSK9 inhibitors (Evolocumab 140 mg or Alirocumab 75 mg every two weeks) (n = 36), and the other group received statins alone (n = 35). All patients underwent measurements of lipid metabolism and arterial stiffness at baseline, 1 month, and 6 months after treatment initiation. Statistical power analysis indicated that the sample size of 71 patients provided sufficient power to detect significant differences. Results: After 1 month, the group treated with statins and PCSK9 inhibitors showed significantly greater reductions in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)] levels compared to the statin-only group (p = 0.027 and p = 0.021, respectively). By the 6-month follow-up, significant reductions were observed in pulse wave velocity (PWV) and ankle-brachial index (ABI) in the combination treatment group (p < 0.05). However, no significant differences were observed between Evolocumab and Alirocumab in terms of arterial stiffness improvement (p > 0.05). Statistical power was sufficient to detect these changes. Conclusions: The findings suggest that PCSK9 inhibitors, when combined with statins, not only improve lipid metabolism but also reduce arterial stiffness, offering potential benefits for vascular health in patients with ACS and atherosclerosis. Further studies with larger sample sizes and longer follow-up periods are necessary to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.